IotaMotion Advances Leadership in Robotic Cochlear Implant Surgery with New Patent
IotaMotion, Inc., a frontrunner in robotic-assisted cochlear implantation systems, has recently announced the issuance of a new patent from the United States Patent and Trademark Office (USPTO), solidifying its leadership in the field. The patent, officially numbered 12.558.123, marks a significant advancement in the company’s portfolio of intellectual property focused on enhancing the precision and control of cochlear implant surgeries.
The flagship product from IotaMotion, the iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System, is now widely recognized as the first of its kind to have received approval from the FDA. This innovative device enables consistent and controlled electrode insertion, minimizing the risk of damaging the delicate structures within the cochlea during surgery. As a result, it addresses a critical gap in care for the over 60 million individuals globally who are potential candidates for cochlear implants but remain untreated due to existing technological limitations.
Mike Lobinsky, CEO of IotaMotion, emphasized the importance of this new patent, stating, "This patent underscores our commitment to innovation and safeguarding our technologies that bring regularity and precision to electrode insertion. As we see our iotaSOFT system being integrated into leading cochlear implant centers, it's paramount that we maintain our competitive edge through robust intellectual property rights."
The iotaSOFT system is particularly remarkable because it facilitates gradual and controlled insertion of the electrode array, which is crucial in preserving cochlear structures—a concern for many clinicians when performing such intricate procedures. FDA clearance for patients aged four and older makes it a versatile tool in managing varied patient needs.
According to the World Health Organization, around 430 million people around the globe experience significant hearing loss, a large portion of whom could greatly benefit from cochlear implants. However, currently, less than 5% of eligible patients undergo this life-changing surgery due to countless barriers, including technological and procedural limitations.
To tackle these challenges, IotaMotion's technological advancements not only aim to increase the number of patients receiving cochlear implants but also promote greater overall patient outcomes through enhanced surgical accuracy. As robotic-assisted surgical technology continues to gain traction across the medical field, the strength of IotaMotion's intellectual property will play a pivotal role in enabling sustained innovation and improving clinical practices in cochlear surgery.
Founded in St. Paul, Minnesota, IotaMotion, Inc. is committed to revolutionizing cochlear implant surgery through advanced robotic assisted technologies. The iotaSOFT system is designed with a specific focus on preserving the fragile intra-cochlear anatomy while ensuring a reliable electrode placement—a feat that is crucial for achieving optimal hearing restoration. Currently available commercially in the United States, the system is also undergoing clinical investigations in various international markets to broaden its impact and accessibility.
For further information, visit www.iotamotion.com and follow IotaMotion on their social media channels for the latest updates.
The flagship product from IotaMotion, the iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System, is now widely recognized as the first of its kind to have received approval from the FDA. This innovative device enables consistent and controlled electrode insertion, minimizing the risk of damaging the delicate structures within the cochlea during surgery. As a result, it addresses a critical gap in care for the over 60 million individuals globally who are potential candidates for cochlear implants but remain untreated due to existing technological limitations.
Mike Lobinsky, CEO of IotaMotion, emphasized the importance of this new patent, stating, "This patent underscores our commitment to innovation and safeguarding our technologies that bring regularity and precision to electrode insertion. As we see our iotaSOFT system being integrated into leading cochlear implant centers, it's paramount that we maintain our competitive edge through robust intellectual property rights."
The iotaSOFT system is particularly remarkable because it facilitates gradual and controlled insertion of the electrode array, which is crucial in preserving cochlear structures—a concern for many clinicians when performing such intricate procedures. FDA clearance for patients aged four and older makes it a versatile tool in managing varied patient needs.
According to the World Health Organization, around 430 million people around the globe experience significant hearing loss, a large portion of whom could greatly benefit from cochlear implants. However, currently, less than 5% of eligible patients undergo this life-changing surgery due to countless barriers, including technological and procedural limitations.
To tackle these challenges, IotaMotion's technological advancements not only aim to increase the number of patients receiving cochlear implants but also promote greater overall patient outcomes through enhanced surgical accuracy. As robotic-assisted surgical technology continues to gain traction across the medical field, the strength of IotaMotion's intellectual property will play a pivotal role in enabling sustained innovation and improving clinical practices in cochlear surgery.
About IotaMotion
Founded in St. Paul, Minnesota, IotaMotion, Inc. is committed to revolutionizing cochlear implant surgery through advanced robotic assisted technologies. The iotaSOFT system is designed with a specific focus on preserving the fragile intra-cochlear anatomy while ensuring a reliable electrode placement—a feat that is crucial for achieving optimal hearing restoration. Currently available commercially in the United States, the system is also undergoing clinical investigations in various international markets to broaden its impact and accessibility.
For further information, visit www.iotamotion.com and follow IotaMotion on their social media channels for the latest updates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.